Post Profile






Immunotherapy drug nearly eliminates severe acute graft-versus-host disease

(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.
read more

share
See more about: American Society

Related Posts


Dr. Mohamad Cherry of Atlantic Hematology Oncology to Lead Meeting Session and Help Present Multiple Studies at Top International Blood Cancer Meeting

Health : Newswise Medical News

Mohamad Cherry, MD, will lead a major session on new discoveries about the most common type of acute adult leukemia and help present results of four major blood cancer studies at the American Society of Hematology (ASH) 59th Annual ...

Bioengineering and specialized therapies yield results for rare, challenging blood diseases

Health : EurekAlert: Health

(American Society of Hematology) In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and th...

Cancer drug ibrutinib found helpful in treating graft versus host disease after transplant

Health : EurekAlert: Health

(American Society of Hematology) A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego shows patients who experience graft-versus-host disease ...

Immunotherapy Strategy Could Be Beneficial for Relapsed Acute Myeloid Leukemia, Preliminary Data Show

Health : Newswise Medical News

Researchers present their preliminary results from the ongoing phase II trial of chemotherapy and pembrolizumab in relapsed or refractory acute myeloid leukemia at the 59th American Society of Hematology Annual Meeting in Atlanta on...

Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Health : Newswise Medical News

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening sev...

Comments


Copyright © 2016 Regator, LLC